DVT Confirmed
Compression ultrasound positive
All Pathways
Internal MedicineManagement
Deep Vein Thrombosis Management (ASH 2020)
Deep Vein Thrombosis Management (ASH 2020): DVT Confirmed → DVT Location → Proximal DVT → Assess Bleeding Risk → Anticoagulant Selection.
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Decision DVT Location
Proximal vs Distal DVT
- Proximal: popliteal vein or above (femoral, iliac)
- Distal: below popliteal (calf veins)
03Action Proximal DVT
Anticoagulation recommended
- Higher PE risk
- Anticoagulation strongly recommended
- Minimum 3 months treatment
04Decision Assess Bleeding Risk
Contraindications to anticoagulation?
- Active bleeding
- Recent major surgery/trauma
- Intracranial pathology
- Severe thrombocytopenia
- HAS-BLED or similar score
05Action Anticoagulant Selection
DOAC preferred over VKA
- DOACs first-line: rivaroxaban, apixaban, edoxaban, dabigatran
- VKA (warfarin) if CKD severe, mechanical valve, antiphospholipid
- LMWH if cancer-associated (or DOAC per guidelines)
- Avoid DOACs if CrCl <25-30
06Decision Home vs Hospital Treatment
Most uncomplicated DVT can be outpatient
- Home treatment suggested for uncomplicated DVT
- Hospital if: extensive iliofemoral, high PE risk
- Hospital if: significant comorbidities, poor support
07Decision Duration of Anticoagulation
Based on provocation and recurrence risk
- Provoked (surgery, trauma, immobilization): 3 months
- Unprovoked: Consider extended/indefinite
- Cancer-associated: Continue while cancer active
08Outcome Provoked DVT
3 months anticoagulation
- Stop after 3 months if major transient risk resolved
- Reassess if recurrent
09Action Unprovoked DVT
Consider extended anticoagulation
- Low bleed risk: suggest indefinite
- High bleed risk: 3 months then reassess
- Patient preference important
- Recurrent unprovoked: indefinite recommended
10Warning Cancer-Associated DVT
Extended anticoagulation
- LMWH or DOAC (per cancer type)
- Continue while cancer active/on treatment
- Edoxaban, rivaroxaban studied in cancer
11Warning IVC Filter Consideration
If anticoagulation contraindicated
- Only if absolute contraindication to AC
- Retrievable filter preferred
- Plan for retrieval when AC safe
- Not routinely with anticoagulation
12Decision Distal DVT
Assess risk factors
- Lower PE risk
- Can consider surveillance vs treatment
- Treat if high-risk features
13Action High-Risk Distal DVT
Anticoagulation recommended
- Severe symptoms
- Multiple veins involved
- Close to popliteal
- Active cancer, prior VTE
- Inpatient, immobile
- Path rejoins step 04Shared downstream outcome
14Action Low-Risk Distal DVT
Serial imaging option
- Repeat US in 1-2 weeks
- If extends proximally: treat
- If stable/resolved: no treatment
- Patient preference matters
- Path rejoins step 07Shared downstream outcome
Guideline Source
ASH 2020 Guidelines for Management of Venous Thromboembolism: Treatment of DVT and PE
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not cover upper extremity DVT in detail
- Cancer-associated VTE may need oncology input
- Pregnancy-related DVT requires OB input
- Drug dosing not included - refer to protocols
- Does not cover thrombolysis patient selection
Contraindicated Populations
pregnancy
Applicable Regions
USEU
EU: NICE and ESC guidelines similar
US: Based on ASH 2020 guidelines
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Deep Vein Thrombosis Management (ASH 2020)?
The Deep Vein Thrombosis Management (ASH 2020) is a management clinical algorithm for Internal Medicine. It provides a structured decision tree to guide clinical decision-making, based on ASH 2020 Guidelines for Management of Venous Thromboembolism: Treatment of DVT and PE.
What guideline is the Deep Vein Thrombosis Management (ASH 2020) based on?
This algorithm is based on ASH 2020 Guidelines for Management of Venous Thromboembolism: Treatment of DVT and PE (DOI: 10.1182/bloodadvances.2020001830).
What are the limitations of the Deep Vein Thrombosis Management (ASH 2020)?
Known limitations include: Does not cover upper extremity DVT in detail; Cancer-associated VTE may need oncology input; Pregnancy-related DVT requires OB input; Drug dosing not included - refer to protocols; Does not cover thrombolysis patient selection. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Deep Vein Thrombosis Management (ASH 2020) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free